Promising Treatment for Acute Respiratory Distress Syndrome

A Phase II clinical trial for Faron Pharmaceuticals Ltd’s Traumakine demonstrated a significant reduction in mortality as a result of acute respiratory distress syndrome (ARDS), according to UK research published in The Lancet Respiratory Medicine.